Trial Profile

An International, Multicenter, Randomized, Double-blind, Phase III Clinical Study to Evaluate the Efficacy and Safety of Toripalimab Injection Combined With Postoperative Adjuvant Chemotherapy Versus Placebo Combined With Postoperative Adjuvant Chemotherapy in Patients With Gastric or Gastroesophageal Junction Adenocarcinoma After Radical Gastrectomy

Status: Active, no longer recruiting

Phase of Trial: Phase III

Latest Information Update: 21 Jan 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Capecitabine (Primary) ; Gimeracil/oteracil/tegafur (Primary) ; Oxaliplatin (Primary) ; Toripalimab (Primary)
Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer
Focus Registrational; Therapeutic Use
Acronyms JUPITER-15
Sponsors Shanghai Junshi Biosciences

13 Jan 2025 Planned primary completion date changed from 31 Mar 2026 to 30 Jun 2026.
13 Jan 2025 Status changed from recruiting to active, no longer recruiting.
31 Mar 2022 According to a Junshi Biosciences media release, In February 2022, first patient was dosed in this study.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com